Evidence map›Paper›PMID 33437479›Full record

ArticleMolecular and clinical oncology2021

Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations.

Masaru Fukahori, Ken Kato, Hirokazu Taniguchi, Rie Ohtomo, Naoki Takahashi, Hirokazu Shoji, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Tetsuya Hamaguchi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Masaru FukahoriDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Ken KatoDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Hirokazu TaniguchiDepartment of Clinical Laboratory, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Rie OhtomoDepartment of Clinical Laboratory, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Naoki TakahashiDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Hirokazu ShojiDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Satoru IwasaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Yoshitaka HonmaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Atsuo TakashimaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Tetsuya HamaguchiDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Yasuhide YamadaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Yasuhiro ShimadaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Yoshinori ItoDepartment of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Jun ItamiDepartment of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Nobukazu HokamuraDepartment of Esophageal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Hiroyasu IgakiDepartment of Esophageal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Yuji TachimoriDepartment of Esophageal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Keisuke MiwaMultidisciplinary Treatment Cancer Center, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan.
Takuji TorimuraDivision of Gastroenterology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Narikazu BokuDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical esophageal squamous cell carcinoma (CESCC) is rare, accounting for 5% of all esophageal carcinomas. Several diagnostic and predictive markers have been studied. However, to the best of our knowledge, no biomarker is known to determine patient management except the clinical stage. The present study aimed to evaluate whether human papilloma virus (HPV) infection, epidermal growth factor receptor (EGFR) and its pathway-related gene mutations, known to be sensitive biomarkers of oropharyngeal carcinomas, could be used as biomarkers for the prediction of the prognosis of patients with CESCC. The present retrospective study included patients with CESCC who received chemoradiotherapy or surgery. HPV infection and the genomic status of

Indexed as

5-bisphosphate 3-kinase catalytic subunit αepidermal growth factor receptoresophageal squamous cell carcinomagene mutationshuman papilloma virusMAPK pathway and phosphatidylinositol-4

Identifiers

PMID33437479
PMCPMC7788557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.